vs
Side-by-side financial comparison of Better Home & Finance Holding Co (BETR) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $44.3M, roughly 2.0× Better Home & Finance Holding Co). On growth, Better Home & Finance Holding Co posted the faster year-over-year revenue change (77.4% vs 17.7%). IOVANCE BIOTHERAPEUTICS, INC. produced more free cash flow last quarter ($-61.9M vs $-167.8M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 41.1%).
Bajaj Finance Limited (BFL) is an Indian deposit-taking non-banking financial company (NBFC-UL) headquartered in Pune. It has 110.64 million customers and holds assets under management worth ₹462,250 crore (US$55 billion), as of September 2025.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
BETR vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.3M | $86.8M |
| Net Profit | $-39.9M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | -3376.8% | -84.7% |
| Net Margin | -3349.0% | — |
| Revenue YoY | 77.4% | 17.7% |
| Net Profit YoY | 32.6% | — |
| EPS (diluted) | $-2.52 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.3M | $86.8M | ||
| Q3 25 | $43.9M | $67.5M | ||
| Q2 25 | $44.1M | $60.0M | ||
| Q1 25 | $32.6M | $49.3M | ||
| Q4 24 | $25.0M | $73.7M | ||
| Q3 24 | $29.0M | $58.6M | ||
| Q2 24 | $32.3M | $31.1M | ||
| Q1 24 | $22.3M | $715.0K |
| Q4 25 | $-39.9M | — | ||
| Q3 25 | $-39.1M | $-91.3M | ||
| Q2 25 | $-36.3M | $-111.7M | ||
| Q1 25 | $-50.6M | $-116.2M | ||
| Q4 24 | $-59.2M | — | ||
| Q3 24 | $-54.2M | $-83.5M | ||
| Q2 24 | $-41.4M | $-97.1M | ||
| Q1 24 | $-51.5M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | -3376.8% | -84.7% | ||
| Q3 25 | -88.9% | -140.7% | ||
| Q2 25 | -81.9% | -189.8% | ||
| Q1 25 | -154.9% | -245.8% | ||
| Q4 24 | -1428.3% | -117.5% | ||
| Q3 24 | -186.5% | -152.1% | ||
| Q2 24 | -127.6% | -327.6% | ||
| Q1 24 | -230.8% | -16464.6% |
| Q4 25 | -3349.0% | — | ||
| Q3 25 | -89.2% | -135.3% | ||
| Q2 25 | -82.2% | -186.2% | ||
| Q1 25 | -155.3% | -235.5% | ||
| Q4 24 | -1437.5% | — | ||
| Q3 24 | -187.0% | -142.7% | ||
| Q2 24 | -128.2% | -312.2% | ||
| Q1 24 | -231.4% | -15800.8% |
| Q4 25 | $-2.52 | — | ||
| Q3 25 | $-2.56 | — | ||
| Q2 25 | $-2.39 | $-0.33 | ||
| Q1 25 | $-3.33 | $-0.36 | ||
| Q4 24 | $-3.92 | $-0.24 | ||
| Q3 24 | $-3.58 | $-0.28 | ||
| Q2 24 | $-2.74 | $-0.34 | ||
| Q1 24 | $-3.41 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $203.4M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $37.2M | $698.6M |
| Total Assets | $1.5B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $203.4M | $297.0M | ||
| Q3 25 | $205.8M | $300.8M | ||
| Q2 25 | $221.5M | $301.2M | ||
| Q1 25 | $228.0M | $359.7M | ||
| Q4 24 | $264.9M | $323.8M | ||
| Q3 24 | $262.1M | $397.5M | ||
| Q2 24 | $378.8M | $412.5M | ||
| Q1 24 | $482.6M | $356.2M |
| Q4 25 | $37.2M | $698.6M | ||
| Q3 25 | $41.9M | $702.3M | ||
| Q2 25 | $76.6M | $698.5M | ||
| Q1 25 | $-102.1M | $767.9M | ||
| Q4 24 | $-58.2M | $710.4M | ||
| Q3 24 | $388.0K | $773.5M | ||
| Q2 24 | $44.9M | $768.5M | ||
| Q1 24 | $76.3M | $680.0M |
| Q4 25 | $1.5B | $913.2M | ||
| Q3 25 | $1.4B | $904.9M | ||
| Q2 25 | $1.2B | $907.4M | ||
| Q1 25 | $1.0B | $966.7M | ||
| Q4 24 | $913.1M | $910.4M | ||
| Q3 24 | $845.2M | $991.1M | ||
| Q2 24 | $957.9M | $964.3M | ||
| Q1 24 | $841.6M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-166.6M | $-52.6M |
| Free Cash FlowOCF − Capex | $-167.8M | $-61.9M |
| FCF MarginFCF / Revenue | -378.6% | -71.3% |
| Capex IntensityCapex / Revenue | 2.7% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-277.9M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-166.6M | $-52.6M | ||
| Q3 25 | $4.2M | $-78.7M | ||
| Q2 25 | $-56.3M | $-67.4M | ||
| Q1 25 | $-57.2M | $-103.7M | ||
| Q4 24 | $-380.0M | $-73.3M | ||
| Q3 24 | $-10.6M | $-59.0M | ||
| Q2 24 | $-220.6M | $-98.4M | ||
| Q1 24 | $-42.8M | $-122.3M |
| Q4 25 | $-167.8M | $-61.9M | ||
| Q3 25 | $4.0M | $-89.5M | ||
| Q2 25 | $-56.7M | $-74.9M | ||
| Q1 25 | $-57.4M | $-109.9M | ||
| Q4 24 | $-383.4M | $-77.5M | ||
| Q3 24 | $-11.7M | $-61.3M | ||
| Q2 24 | $-221.8M | $-98.9M | ||
| Q1 24 | $-43.3M | $-126.5M |
| Q4 25 | -378.6% | -71.3% | ||
| Q3 25 | 9.1% | -132.7% | ||
| Q2 25 | -128.5% | -124.9% | ||
| Q1 25 | -176.3% | -222.8% | ||
| Q4 24 | -1534.6% | -105.1% | ||
| Q3 24 | -40.5% | -104.6% | ||
| Q2 24 | -687.6% | -317.9% | ||
| Q1 24 | -194.5% | -17685.3% |
| Q4 25 | 2.7% | 10.7% | ||
| Q3 25 | 0.5% | 16.1% | ||
| Q2 25 | 0.9% | 12.4% | ||
| Q1 25 | 0.6% | 12.6% | ||
| Q4 24 | 13.6% | 5.7% | ||
| Q3 24 | 4.1% | 3.9% | ||
| Q2 24 | 3.9% | 1.4% | ||
| Q1 24 | 2.1% | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BETR
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
